After a year on the U.S. market, the Intersurgical StarMed CaStar R Hood is saving lives. The StarMed Hood is now being used in several hospitals and hospital systems across the country with outstanding results.
Also Read: SHL Medical Publishes its Molly Modular Autoinjector Platform Technology White Paper
This hood-based patient interface designed to provide a more comfortable alternative to traditional methods of Continuous Positive Airway Pressure (CPAP) and Non-Invasive Ventilation (NIV) is giving patients in respiratory distress a breath of fresh air. The unique and innovative Intersurgical StarMed CaStar R Hood, a highly effective and comfortable patient interface used to treat patients with life-threatening Acute Respiratory Distress Syndrome (ARDS), was issued an Emergency Use Authorization by the FDA. The hood debuted in the U.S. in response to the surge in demand for ventilatory intervention.
Developed by Intersurgical—a leading global medical device designer, manufacturer, and supplier of a wide range of high-quality products for respiratory support—the StarMed Hood provides a more comfortable and innovative solution for patients struggling to breathe.
The pressurized hood can be used for hypoxemic patients, those with critically low levels of oxygen in their bloodstream, as well as for hypercapnic patients, who have excessive carbon dioxide in the bloodstream. A well-tolerated, comfortable, and lightweight interface that fits over the patient’s head, the StarMed Hood forms a semi-enclosed, pressurized environment that assists the patient’s lungs, making it easier to breathe. In addition, a patient wearing the StarMed Hood can eat, sleep, and communicate normally.
The hood interface reduces the risks associated with traditional methods of CPAP therapy and NIV delivery, such as skin breakdown, lesions, and irritation. Use of the StarMed Hood could also reduce the need for patients to be intubated, a process that requires patients to be put into a medically induced coma and increases risks of infection. Avoiding intubation could reduce overall mortality rates for ARDS patients by as much as 48 percent.